Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.
Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.
复制标题
DOI：
10.1097/cce.0000000000000111
复制
发表时间：
2020-04-01
影响因子：
--
通讯作者：
Meduri, G Umberto
中科院分区：
文献类型：
--
作者：
Villar, Jesus;Confalonieri, Marco;Meduri, G Umberto
2019年12月，中国武汉出现2019新型冠状病毒病（COVID-19）相关肺炎。2020年3月14日，世界卫生组织（WHO）宣布冠状病毒爆发为大流行病，在127个国家确诊病例。医疗机构的这一前所未有的负担对于ICU和治疗机械通气患者的医务人员来说尤其沉重。COVID-19感染引起的急性呼吸窘迫综合征（ARDS）的发生率在17%至41%之间（1-3）。ARDS可能需要数周的机械通气（MV），并且与不可接受的高死亡率相关。在世界范围内，成千上万的病人因缺乏机械呼吸机而得不到救生支持。这是前所未有的全球紧急情况，却没有可行的解决办法。因此，任何旨在减少MV持续时间和死亡率的干预措施都可能对公共卫生和国家安全产生重大影响。
In December 2019, pneumonia associated with the novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. On March 14, 2020, the World Health Organization (WHO) declared the coronavirus outbreak a pandemic with confirmed cases in 127 countries. This unprecedented load on healthcare institutions is particularly overwhelming for ICUs and medical personnel treating mechanically ventilated patients. The occurrence rate of acute respiratory distress syndrome (ARDS) with COVID-19 infection varied between 17% and 41%(1–3). ARDS may require weeks of mechanical ventilation (MV) and is associated with an unacceptably high mortality rate. Worldwide, thousands of patients are denied life-saving support for lack of mechanical ventilators. This is unprecedented global emergency without a workable solution. Thus, any intervention directed at decreasing duration of MV and mortality could have a great impact on public health and national security.